BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $902.94 million. The enterprise value is $1.36 billion.
| Market Cap | 902.94M |
| Enterprise Value | 1.36B |
Important Dates
The next confirmed earnings date is Monday, May 6, 2024, before market open.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 206.15 million shares outstanding. The number of shares has increased by 3.38% in one year.
| Shares Outstanding | 206.15M |
| Shares Change (YoY) | +3.38% |
| Shares Change (QoQ) | +6.26% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 88.13% |
| Float | 190.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.72 |
| Forward PS | 2.24 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.31
| Current Ratio | 3.31 |
| Quick Ratio | 2.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -43.60% |
| Return on Capital (ROIC) | -26.38% |
| Revenue Per Employee | $618,306 |
| Profits Per Employee | -$422,647 |
| Employee Count | 536 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 0.17 |
Taxes
In the past 12 months, BCRX has paid $310,000 in taxes.
| Income Tax | 310,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.44% in the last 52 weeks. The beta is 1.93, so BCRX's price volatility has been higher than the market average.
| Beta (1Y) | 1.93 |
| 52-Week Price Change | -42.44% |
| 50-Day Moving Average | 5.16 |
| 200-Day Moving Average | 6.06 |
| Relative Strength Index (RSI) | 34.79 |
| Average Volume (30 Days) | 3,107,385 |
Short Selling Information
The latest short interest is 32.25 million, so 15.64% of the outstanding shares have been sold short.
| Short Interest | 32.25M |
| Short Previous Month | 30.55M |
| Short % of Shares Out | 15.64% |
| Short % of Float | 16.90% |
| Short Ratio (days to cover) | 9.45 |
Income Statement
In the last 12 months, BCRX had revenue of $331.41 million and -$226.54 million in losses. Loss per share was -$1.18.
| Revenue | 331.41M |
| Gross Profit | 326.75M |
| Operating Income | -103.71M |
| Pretax Income | -226.23M |
| Net Income | -226.54M |
| EBITDA | -116.34M |
| EBIT | -117.99M |
| Loss Per Share | -$1.18 |
Balance Sheet
The company has $390.79 million in cash and $848.71 million in debt, giving a net cash position of -$457.92 million or -$2.22 per share.
| Cash & Cash Equivalents | 390.79M |
| Total Debt | 848.71M |
| Net Cash | -457.92M |
| Net Cash Per Share | -$2.22 |
| Equity / Book Value | -455.53M |
| Book Value Per Share | -2.21 |
| Working Capital | 345.98M |
Cash Flow
In the last 12 months, operating cash flow was -$95.14 million and capital expenditures -$2.17 million, giving a free cash flow of -$97.31 million.
| Operating Cash Flow | -95.14M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | -97.31M |
| FCF Per Share | -$0.51 |
Margins
Gross margin is 98.59%, with operating and profit margins of -31.29% and -68.36%.
| Gross Margin | 98.59% |
| Operating Margin | -31.29% |
| Pretax Margin | -68.26% |
| Profit Margin | -68.36% |
| EBITDA Margin | -35.10% |
| EBIT Margin | -35.60% |
| FCF Margin | -29.36% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.38% |
| Shareholder Yield | -3.38% |
| Earnings Yield | -25.09% |
| FCF Yield | -10.78% |
Analyst Forecast
The average price target for BCRX is $13.83, which is 215.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.83 |
| Price Target Difference | 215.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 19.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -3.3 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.3 |
| Piotroski F-Score | 3 |